Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00844922
Other study ID # P05842
Secondary ID EudraCT #: 2004-
Status Completed
Phase Phase 2
First received February 11, 2009
Last updated December 30, 2014
Start date September 2005
Est. completion date June 2006

Study information

Verified date December 2014
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized to Org 34517 (SCH 900636), regardless of dose, were titrated to 900 mg Org 34517. Patients in this trial took their study medication for 2 weeks in order to study the safety and tolerability of Org 34517.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date June 2006
Est. primary completion date June 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of previous trial 28130;

- have a CGI of Severity score of 3 or greater at Day 43 of previous trial 28130 and at Day 1 of current trial 28133, or a lower score when the investigator is of the opinion that further resolution of symptoms is warranted;

- be on a stable dose of 'usual treatment', which must consist of an antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes.

Exclusion Criteria:

- had experienced any of the following significant safety outcomes in previous trial 28130:

- severe breakthrough bleeding;

- diagnosis of prostatitis;

- abnormal level of testosterone at Day 15 of previous trial 28130;

- any adverse event deemed relevant for exclusion in trial 28133 by the investigator.

- had an abnormal PSA test at Day -7 of previous trial 28133

- were at significant risk of committing suicide, as indicated by a score greater than 9 on the revised ISST at Day -7 or Day 1;

- were currently treated with carbamazepine or valproate, midazolam, or clozapine;

- had been treated with electroconvulsive therapy (ECT) in the current episode;

- were currently treated with more than one antidepressant, antipsychotic, or mood stabilizer;

- had 'usual treatment' started or discontinued in the 2 weeks before Day 1;

- had a 'usual treatment' dose change within one week prior to Day 1;

- had any clinically unstable or uncontrollable renal, hepatic, respiratory, hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy;

- had known hypersensitivity reactions to glucocorticoid antagonists;

- had any clinically significant abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or ECG results, or a clinically significant abnormal outcome at the physical examination at Day -7;

- had a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Day -7;

- had any untreated or uncompensated clinically significant endocrine disorder;

- were using hormone replacement therapy at Day -7;

- required concomitant treatment with corticosteroids (topical use was allowed);

- women of childbearing potential without adequate contraception

- women with a positive pregnancy test at Day -7 or 1, or are breast feeding mothers.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
SCH 900636
Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the "usual treatment" for psychotic major depression.
Placebo
Placebo

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability measures (vital signs, AEs) 4 weeks No
Secondary 17-item Hamilton Rating Scale for Depression (HAMD) total score 4 weeks No
Secondary proportion of BPRS 30% responders; proportion of subjects with sustained BPRS 30% response 4 weeks No
Secondary proportion of HAMD 50% responders; proportion of subjects with sustained HAMD 50% response 4 weeks No
Secondary clinical global impression (CGI) 4 weeks No
Secondary PANNS total score 4 weeks No
Secondary PANSS positive scale score, PANSS negative scale score, PANSS general psychopathology score 4 weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A